Table 1.
Baseline characteristics of the eCRC population.
| Covariate | Study Patients (N = 94) |
|---|---|
| Age at study entry, years | |
| Median age (range) | 78 (70–89) |
| Tumor localization; n (%): | |
| • Left/Rectum | 57 (61) |
| • Right | 37 (39) |
| Tumor size; n (%): | |
| • T1 | 1 (1) |
| • T2 | 6 (6) |
| • T3 | 72 (77) |
| • T4 | 7 (7) |
| • NA * | 8 (9) |
| Nodal involvement; n (%): | |
| • N0 | 41 (44) |
| • N1 | 28 (30) |
| • N2 | 17 (18) |
| • NA * | 8 (9) |
| Histologic grade; n (%): | |
| • Grade 1 | 6 (6) |
| • Grade 2 | 67 (72) |
| • Grade 3 | 17 (18) |
| • NA | 4 (4) |
| Stage; n (%): | |
| • Stage I | 3 (3) |
| • Stage II | 42 (45) |
| • Stage III | 41 (43) |
| • NA * | 8 (9) |
| Relapse; n (%): | |
| • Not relapsed | 65 (69) |
| • Relapsed | 29 (31) |
| Treatment; n (%): | |
| • Neoadjuvant chemo-radiotherapy | 8 (9) |
| • Adjuvant CT | 56 (59) |
| • No treatment | 30 (32) |
med [Q1; Q3] (min; max) for numerical variables N (%) for categorical variables. * patients with rectal cancer pre-treated with neoadjuvant chemo-radiotherapy.